Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 7, 1998, Pages 2399-2404

  Ryan, Alice S ^b   Egan, Josephine M ^a   Habener, Joel F ^c,d   Elahi, Dariush ^a,b,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-37]; GLUCOSE; HYDROCORTISONE; INSULIN; SOMATOSTATIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; MALE; NEUROENDOCRINOLOGY; NORMAL HUMAN; PRIORITY JOURNAL;

ADRENOCORTICOTROPIC HORMONE; ADULT; BLOOD GLUCOSE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PEPTIDE FRAGMENTS; PEPTIDES; REFERENCE VALUES; SECRETORY RATE; SOMATOSTATIN;

EID: 0031756220     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.7.2399     Document Type: Article

References (40)

1. Orskov C. 1992 Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia. 35:701-711.
2. Kreymann B, Ghatei MA, Williams G, Bloom SR. 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1303.
3. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt WOC. 1995 Insulinotropic actions of IV glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol. 32:13-16.
4. Creutzfeldt WOC, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. 1996 Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36) amide in type I diabetic patients. Diabetes Care. 19:580-586.
5. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF. 1992 Insulinotropic action of glucagon-like peptide-1 (7-37) in diabetic and nondiabetic subjects. Diabetes Care. 15:270-276.
6. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. 1994 The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 51:63-74.
7. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J. 1994 Glucagon-like peptide-1 (7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology. 135:2070-2075.
8. Valverde I, Morales M, Clemente F, et al. 1994 Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett. 349:313-316.
9. Miki H, Nishimura T, Mineo I, et al. 1996 Glucagon-like peptide (7-36 amide] increases insulin stimulated glucose uptake in isolated fat adipocytes. Biochim Biophys Acta. 1312:132-136.
10. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I. 1994 Potent glycogenic effect of GLP-1 (7-36) amide in rat skeletal muscle. Diabetologia. 37:1163-1166.
11. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. 1994 Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest. 93:2263-2266.
12. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. 1992 Antidiabetogenic effect of glucagon-like peptide-1 [7-36 amide] in normal subjects and patients with diabetes. N Engl J Med. 326:1316-1322.
13. Furnsinn C, Ebner K, Waldbausl W. 1995 Failure of GLP-1 (7-36) amide to affect glycogenesis in rat skeletal muscle. Diabetologia. 38:864-867.
14. Toft-Nielsen M, Madsbad S, Holst JJ. 1996 The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes. 45:552-556.
15. National Diabetes Data Group. 1979 Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 28:1039-1057.
16. Kieffer TJ, McIntosh CHS, Pederson RA. 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 136:3585-3596.
17. Deacon CF, Johnsen AH, Holst JJ. 1995 Degradation of glucagon-like peptide-1 by human plasma in vitro yields an n-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 80:952-957.
18. Steele R. 1959 Influences of glucose loading and injected insulin on hepatic glucose output. Ann NY Acad Sci. 82:420-430.
19. McGuire EAH, Helderman JH, Tobin JD, Andres R, Berman M. 1976 Effects of arterial vs. venous sampling on analysis of glucose kinetics in man. J Appl Physiol. 41:565-573.
20. Sherwin RS, Kramer KJ, Tobin JD, et al. 1974 A model of the kinetics of insulin in man. J Clin Invest. 53:1481-1492.
21. Ernhardt RC, Kindler DD, Weaver AM, et al. 1993 Hyperinsulinemia after pancreatic transplantation: prediction by a novel computer model and in vivo verification. Ann Surg. 218:428-443.
22. 3H]-glucose infusion, and labelled or unlabelled glucose infusates. Diabetes Med. 9:840-849.
23. Soeldner JS, Slone D. 1965 Critical variables in the radioimmunoassay of serum insulin using the double antibody technique. Diabetes. 14:771-779.
24. Faloona GR, Unger RH. 1974 Glucagon. In: Jaffe BM, Behrman HR, eds. Methods of hormone radioimmunoassay. New York: Academy Press; 317-334.
25. Somogyi M. 1984 Determination of blood sugar. J Biol Chem. 10:69-73.
26. Ashcraft MW, Van Herle AJ, Vener SL, Geffner SL. 1982 Serum Cortisol levels in Cushing's syndrome after low- and high-dose dexamethasone suppression. Ann Intern Med. 97:21-26.
27. Oelkers W, Diederich S, Bahr V. 1992 Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab. 75:259-264.
28. Aponte GW, Gross D, Yamada T. 1985 Capillary orientation of rat pancreatic D-cell processes: evidence for endocrine release of somatostatin. Am J Physiol 249:G599-G606.
29. Insel PA, Liljenquist TE, Tobin JD, et al. 1975 Insulin control of glucose metabolism in man: a new kinetic analysis. J Clin Invest. 55:1057-1066.
30. Radzuik J, Norwich KH, Vranic M. 1974 Measurement and validation of non-steady turnover rates with application to the insulin and glucose systems. Fed Proc. 33:1855-1865.
31. Snedecor GW, Cochran WG. 1979 Statistical methods. Ames: Iowa University Press; 59-65.
32. Wettergren A, Scholdager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. 1993 Truncated GLP-1 (proglucagon 78-107 amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 38:665-673.
33. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. 1996 Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 81:327-332.
34. Dupre J, Behme MT, Hramiak IM, et al. 1995 Glucagon-like peptide 1 reduces postprandial glycemic excursions in IDDM. Diabetes. 44:626-630.
35. D'Alessio DA, Prigeon RL, Ensinck JW. 1995 Enterai enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. Diabetes. 44:1433-1437.
36. Bergman RN, Ider YZ, Bowden CR, Cobelli C. 1979 Quantitative estimation of insulin sensitivity. Am J Physiol 236:E667-E677.
37. Prigeon RL, Roder ME, Porte D, Kahn SE. 1996 The effect of insulin dose on the measurement of insulin sensitivity by the minimal model technique. J Clin Invest. 97:501-507.
38. Beak SA, Small CJ, Ilovaiskala I, et al. 1996 Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on TSH cells. Endocrinology. 137:4130-4138.
39. Larsen PJ, Tang-Christensen M, Jessop DS. 1997 Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology. 138:4445-4455.
40. Flint A, Astrup A, Holst JJ. 1998 Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 101:515-520.